Ctic stock earnings
CTI Biopharma Corp (NASDAQ:CTIC) The current consensus among 2 polled investment analysts is to Buy stock in CTI Earnings and Sales Forecasts (CTIC) stock price, news, historical charts, analyst ratings and financial information from CTIC (U.S.: Nasdaq) Per-Share Earnings, Actuals and Estimates. 1 Year % Chg -9.19. Market Cap 70.7M. Shares Outstanding 73.7M. Beta 1.58. Dividend (Yield) -. Div Amount -. Ex Div Date -. Earnings Date 2020-05-03. How do you think NASDAQ:CTIC will perform against the market? Paclitaxel analogue Opaxio wasn't mentioned in the last earnings PR, although a phase III CTIC: Get the latest CTI BioPharma stock price and detailed information including CTIC news, EARNINGS SUMMARY: Details of CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI” or “the Company”) today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration Cell Therapeutics, Inc. (NASDAQ: CTIC) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and
Mar 12, 2020 (Nasdaq: CTIC) today reported its financial results for the fourth Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.
View CTI BioPharma's (NASDAQ:CTIC) earnings history, next earnings date and earnings MarketBeat - Stock Market News and Research Tools logo. Sign up Mar 3, 2020 CTI BioPharma Corp. (CTIC) latest earnings report: revenue, EPS, surprise, history, news and analysis. Find the latest and the upcoming CTI BioPharma earnings report Mar 23, 2020 as well as EPS Forecast and CTIC top analyst price target The TipRanks Smart Score analyzes stocks based on 8 factors extracted from our unique datasets. (CTIC) stock quote, history, news and other vital information to help you with your stock trading and investing. Earnings Date, Mar 12, 2020. Forward Dividend N/A, EPS Growth Rate, N/A. Average EPS % Beat Rate, -13.4%, Revenue Growth Rate, N/A. Average % Move 1-Wk after EPS, -25.7%, Normal Earnings Time
(CTIC) stock quote, history, news and other vital information to help you with your stock trading and investing. Earnings Date, Mar 12, 2020. Forward Dividend
How do you think NASDAQ:CTIC will perform against the market? Paclitaxel analogue Opaxio wasn't mentioned in the last earnings PR, although a phase III CTIC: Get the latest CTI BioPharma stock price and detailed information including CTIC news, EARNINGS SUMMARY: Details of CTI BioPharma Corp. (Nasdaq: CTIC) (“CTI” or “the Company”) today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration Cell Therapeutics, Inc. (NASDAQ: CTIC) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and These institutions hold a total of 65,670,333 shares. Largest shareholders include Bvf Inc/il, Orbimed Advisors Llc, Stonepine Capital Management, LLC, NEA (LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript. 25 days ago - Seeking Alpha - Healthcare. Summary. Lineage Cell Therapeutics, Inc. (
(LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript. 25 days ago - Seeking Alpha - Healthcare. Summary. Lineage Cell Therapeutics, Inc. (
(Nasdaq: CTIC) (“CTI” or “the Company”) today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration Cell Therapeutics, Inc. (NASDAQ: CTIC) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and These institutions hold a total of 65,670,333 shares. Largest shareholders include Bvf Inc/il, Orbimed Advisors Llc, Stonepine Capital Management, LLC, NEA
(CTIC) stock quote, history, news and other vital information to help you with your stock trading and investing. Earnings Date, Mar 12, 2020. Forward Dividend
Oct 10, 2019 TSLA stock is among the most polarizing in the market, and this is shown by the volatility exhibited by the company's shares this year. A look at
N/A, EPS Growth Rate, N/A. Average EPS % Beat Rate, -13.4%, Revenue Growth Rate, N/A. Average % Move 1-Wk after EPS, -25.7%, Normal Earnings Time CTI Biopharma Corp (NASDAQ:CTIC) The current consensus among 2 polled investment analysts is to Buy stock in CTI Earnings and Sales Forecasts (CTIC) stock price, news, historical charts, analyst ratings and financial information from CTIC (U.S.: Nasdaq) Per-Share Earnings, Actuals and Estimates.